Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of erlotinib + sorafenib in chemotherapy-naive advanced non-small cell lung cancer
NL-OMON31390Phase 2Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and sorafenib in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoints: No progression rate at 6 weeks and Pharmacokinetics of erlotinib with concomitant sorafenib. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
erlotinibsorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON31390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31390.